Abstract: Pharmacokinetic limitations affect drug bioavailability determining the loss or the reduction of the pharmacological effects. The Gastro Intestinal tract (GI) and the Blood Brain Barrier (BBB) are the most important restrictive and selective physiological lines of defense of the organism. Although several parameters such as LogP, LogD and K a have been extensively employed for determining drug bioavailability, the active transports, present in these biological barriers, play an important role for dosing and limiting cell drugs concentration. In particular, ATP Binding Cassette (ABC) transporters are involved in the active transport both in GI and BBB. Their strategic activity and biochemical and pharmacological role are herein treated.
INTRODUCTION
The therapeutic effect of many drugs is due to their ability to cross cellular barriers for targeting the biological sites. Usually it is accepted that lipophilic drugs can cross these barriers in the absence of specific carriers because they freely diffuse across the plasma membrane whereas hydrophilic and charged compounds employ transporter mechanisms to cross cell membranes. This is only a first aspect of the question but another important aspect involves the efflux of these drugs by active transporters; they modulate the absorption and the accumulation of drugs and toxic substances into the cells. In this paper we discuss the critical aspects related to drug efflux by ABC transporters considering the two major physiological barriers involved in drug-transport ABC-mediated: the Gastro Intestinal tract (GI) and the Blood Brain Barrier (BBB).
ACTIVE TRANSPORT IN GASTROINTESTINAL TRACT
Oral drug absorption from the intestine is a function of different drug parameters: a) solubility in GI fluids; b) metabolic stability; c) permeability [1, 2] . Therefore, these parameters modulate the oral bioavailability of drugs into the systemic circulation. Drug absorption across the intestinal membrane is due to passive and active absorption [3] . Passive absorption occurs through the cell membrane of enterocytes (transcellular way) or through the tight junctions between the enterocytes (paracellular way) as depicted in Fig. (1) .
Active absorption can be carrier-mediated or a facilitated diffusion. Lipophilic molecules are absorbed through the intestinal epithelium by passive diffusion whereas hydrophilic molecules by a carrier-mediated process. Some small hydrophilic compounds are transported through the paracellular junction [1] . As a first step transcellular absorption involves the crossing of the apical membrane from lumen to blood. After transport across the cytosol, the drug overcomes the basolateral membrane reaching the blood. Usually, hydrophilic drugs employ the same carriers of nutrients and micronutrients whereas lipophilic molecules employ passive transcellular absorption [1, 4] (Fig. (2) ).
Active efflux pumps, belonging to ABC transporters such as P-gp and MRP2, are localized on the apical membrane. These transporters can extrude drugs back into the lumen [5] [6] [7] [8] with the aim of dosing the absorption and the accumulation of drugs and toxic substances into the cells and of facilitating the intestinal clearance of compounds present in the blood (Fig. (3) ).
ABC transporters efflux unmodified drugs and/or drugs metabolites as substrates (Fig. (4) ) when these compounds interact with cytochrome P450 (Phase I) and with conjugating enzymes (Phase II). Intestinal CYP3A4, the most important cytochrome isoform involved in first pass
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metabolism, regulates the systemic availability of many orally administered drugs. It has been reported that in small intestine P-gp and CYP3A4 are localized on the villus tip of enterocytes [7, [9] [10] [11] [12] where they synergistically act. Each of the two metabolic phases can transform the metabolized drugs into efflux pumps substrates [13] .
ATP-BINDING CASSETTE (ABC) FAMILY IN GASTROINTESTINAL TRACT
ABC subfamilies involved in intestinal transport are the MDR subfamily, including MDR1, MDR3, BSEP, and the MRP subtype, including MRP1-9 [2] . Moreover, also BCRP is considered to be involved in the intestinal transport [14, 15] .
ABCB SUBFAMILY
P-glycoprotein
ABCB1, also known as P-gp, displays a large spectrum of transported substrates in particular lipophilic and cationic compounds although P-gp potential substrates preferentially are anticancer agents, antibiotics, antivirals, calcium channel blockers, and immunosuppressive agents. At this list of biologically active compounds food and vegetables should also be added [3, 16] . P-gp is highly localized in kidney, adrenal gland, liver, colon and lung, and also as basal level in prostate, skin, spleen, heart, skeletal muscle, stomach and ovary and in BBB [17, 18] . This membrane apical localization plays a critical role in the efflux of xenobiotics and toxins into the intestinal lumen, bile, urine, and blood [7, 11, 12, [18] [19] [20] . The apical P-gp expression allows the efflux transport of several anticancer drugs both from basolateral to apical and from blood to lumen modulating their oral bioavailability.
MDR3
MDR3 has been firstly identified as a canalicular phospholipid translocator [21, 22] and the studies to investigate its role were carried out in human MDR3 gene mutation experiments observing its involvement in pathologies that results in phospholipid secretion by the liver and high serum -glutamyltransferase levels [23] .
MDR3 protein effluxes several drugs such as digoxin, and several antineoplastic agents such as vinblastine, and paclitaxel [24] although the relationship between MDR3 and multidrug resistance has to be demonstrated yet.
BSEP (Bile Salt Export Pump)
BSEP, also known as Sister of P-gp (SP-gp) for its close sequence homology with P-gp, was first cloned from porcine liver [25] . BSEP mediates bile acid transport across the canalicular membrane of hepatocytes downregulating intracellular bile acid concentrations and regulating the enterohepatic circulation of bile acids.
Although BSEP is a Sister P-gp protein, it is not involved in the efflux of several chemotherapeutic agents that are specific P-gp substrates. Consequently, BSEP in drug disposition is less involved than its close relative P-gp.
ABCC SUBFAMILY MRP1
MRP1 (ABCC1) is localized in high levels in intestine, brain, kidney, lung, and testis, and lower expression was found in liver [26] [27] [28] [29] . MRP1 is present in basolateral membranes of polarized epithelial cells, renal distal and collecting tubules [30] , and liver [31, 32] . Although MRP1 involvement in the intestinal drug disposition is not completely clarified, its ability to confer resistance to antineoplastic drugs has been demonstrated [33] .
MRP1 protein effluxes several conjugated metabolites, such as glutathione conjugates (leukotriene C4 and 2,4-dinitrophenyl-S-glutathione), bilirubin glucuronides, estradiol-17--glucuronide, and dianionic bile salts [34] [35] [36] [37] indicating its involvement in detoxification of endogenous metabolites. 
Metabolising enzymes
MRP1 localization at basolateral level suggests that this protein protects cells through the efflux of substrates into the blood. Indeed, MRP1 is responsible for the elimination of toxins and this action is more effective when it is coupled with apical P-gp. Both MRP1 and P-gp expression was higher in tumour tissues treated with chemotherapeutic agents than in untreated tumours [38] .
MRP2
MRP2 (ABCC2), originally identified in human liver as the canalicular multispecific organic anion transporter (cMOAT) [39] , is highly expressed in liver, intestine, and kidney tubules [6, 40, 41] . MRP2 is localized at the apical membranes of these tissues [6, 40, 42, 43] . This pump [44] . Considering the transported substrates, MRP2 contributes to the detoxification by secreting metabolites into the bile. MRP2 protein also transports potentially toxic or beneficial dietary constituents, such as flavonoids [8, 45] .
It has been hypothesized that the MRP2 pump is coexpressed with enzymes involved in Phase II metabolism, because of the fact that this pump transports several conjugated compounds. Among Phase II metabolizing enzymes, Glutathione-S-transferase catalyses the conjugation of glutathione to a range of electrophilic compounds then exported by MRP transporters. Glutathione-S-transferases are reported in several isoforms ( , μ, , , , and microsomal). Human GST -isoform expression is reported in duodenum and small intestine decreasing from proximal to distal small intestine, and from small intestine to colon [46] . Moreover, a co-expression of MRP2 with other Phase II metabolizing enzymes such as UDP-glucuronosyltransferases (UGT) has been reported. These enzymes catalyse the conjugation of glucuronic acid to nucleophilic CYP3A4. Therefore, given the co-expression with Phase II metabolizing enzymes, is possible to assert that MRP2 plays a synergistic role in intestinal drug detoxification and excretion.
MRP3
The presence of MRP3 (ABCC3) has been reported in liver, small intestine and colon and, differently from MRP2, its expression is high in the ileum and colon [47] . MRP3 is localized to the basolateral membrane [48] showing a similar substrate specificity with MRP2 and BSEP, because it effluxes bile salts [49, 50] . The affinity for bile salts, and its expression in the intestine suggests a possible involvement of MRP3 in bile salt uptake.
MRP4
MRP4 (ABCC4) has been detected in jejunum, kidney, brain, lung [51] [52] [53] [54] and it is structurally more similar to P-gp than to the other "typical" MRP transporters. MRP4 is expressed on the apical membranes of human renal proximal tubule cells [53] and basolaterally in tubuloacinar cells of the prostate gland [55] . MRP4 transports folic acid, folinic acid (leucovorin), methotrexate [56] , cAMP, cGMP, estradiol-17--glucuronide, and bile acids [57] [58] [59] [60] and its physiological role regards prostaglandin-E cellular release. The apical localization both in kidney and in the intestine suggests that MRP4 is involved in biliary secretion of nucleoside phosphonate analogues and it limits their intestinal absorption contributing to their poor oral bioavailability.
MRP5
MRP5 (ABCC5) is structurally similar to MRP4 and it is reported basolaterally in colon, liver, kidney, skeletal muscle [51, 61] and brain [29] . MRP5 does not confer resistance to antineoplastic drugs and in the meantime there is no evidence of intestinal drug disposition MRP5-mediated.
MRP6
MRP6 (ABCC6) is highly expressed in kidney, liver, duodenum, colon, brain, and salivary gland [29, 62, 63] . It was hypothesized that MRP6 mediates the transport of several natural cytotoxic agents that are also substrates for MRP1-3, including etoposide, doxorubicin and cisplatin [64] .
MRP7-9
Recent reports indicate that MRP7 (ABCC7) is detected in liver, kidney, colon, spleen, skin, stomach, and testis [65] while MRP8 (ABCC8) is highly expressed in breast cancer, and at moderate levels, in normal breast, testis, and, at low levels, in liver, brain, and placenta [66] . Two variants of MRP9 (ABCC9) have been identified, one subtype reported in breast cancer, normal breast, and testis, and the other in brain, skeletal muscle, and ovary [67] . Although MRPs7-9 are not functionally classified, their important roles in drug resistance and drug efflux have been hypothesized.
ABCG SUBFAMILY BCRP
BCRP (ABCG2) is an ABC half-transporter expressed in breast, ovary, small intestine, colon, and liver [68, 69] . BCRP mediates secretory transport of drugs in polarized cancer cell lines of breast, colon and stomach [70] and has a large effect on the oral bioavailability of the anticancer drugs. Since the in vivo data demonstrate that BCRP effluxes the same substrates as P-gp [71] , these findings suggest BCRP as halftransporter compared to P-gp in regulating drug absorption and disposition. On the other hand, BCRP pump has six transmembrane domains with respect to twelve transmembrane domains of P-gp.
ABC TRANSPORTERS IN GASTROINTESTINAL TRACT AND IN PERIPHERAL REALATED ORGANS
In 
ACTIVE TRANSPORT IN THE BLOOD BRAIN BARRIER
Drug availability into the brain is modulated by physical barriers such as Blood Brain Barrier (BBB) and Blood CerebroSpinal Fluid Barrier (BCSFB). BBB and BCSFB are different in location, size, morphology, and function [72] [73] [74] . BBB regulates and preserves the brain acting as a physical and metabolic barrier. The presence of tight junctions (zonulae occludens) [75] between endothelial cells and the lack of fenestrae and pinocytotic vesicles in the cerebral arterioles, capillaries, and endothelium venules modulate brain uptake. BCSFB is formed by the choroid plexus epithelial cells which are connected by tight junctions, whereas the capillaries are fenestrated.
BBB modulates molecules access to the brain by two processes: 1) passive diffusion or 2) active transport [72] . The first process mediates lipid and small nonpolar molecules access while the second process is mediated by several membrane transporters modulating the influx or efflux of various essential substrates (electrolytes, nucleosides, amino acids, and glucose). Although lipophilicity has been considered a facilitating aspect to permeate the lipid bilayer, several molecules and drugs display lower brain permeability despite a favourable lipophylicity.
The molecules access trough BBB is performed by two possible mechanisms: (i) carrier-mediated transport, (ii) active efflux transport. Usually, CNS penetration of small molecules is modulated by carriers and/or active transporters [76, 77] whereas large molecules permeation can be receptormediated. Carriers prevalently mediate the influx of substrates from brain to blood, although some carriers can modulate the opposite flux while the active transport modulates the efflux from brain to blood.
Molecules access from brain to blood is a process mediated by two transporter families including an energydependent and energy-independent transporters [74] . ABC transporters are energy-dependent system and they are prevalently localized at the luminal membrane. Solute Carrier (SLC) transporters are energy-independent systems and are localized at the abluminal membrane of the brain capillary endothelial cells [78, 79] .
ATP-BINDING CASSETTE (ABC) FAMILY IN BBB P-glycoprotein
High levels of P-gp are reported in the luminal membrane of the endothelial cells constituting BBB, BCSFB, and blood-testis barrier [76, [80] [81] [82] . Such strategic localization gives P-gp a physiologically crucial role. P-gp links drugs in the core of the lipid bilayer and flips them into blood [83] . Pgp exerts a protective function in BBB; for example, recent results reported a significant correlation between Parkinson's disorder induced by pesticides and ABCB1 gene polymorphism (C3435T). The mutation of this gene increases the toxic effects of pesticides and of other toxic xenobiotics Hepatocytes usually effluxed by P-gp. In Alzheimer's disease, the expression of P-gp in blood vessels contributes to the accumulation of -amyloid: the first step to diagnose this pathology suggesting a P-gp involvement in Alzheimer's disease [84, 85] . Moreover, the differences in P-gp expression and dislocation in the brain area could be correlated to other diseases such as epilepsy. In this case, P-gp is present both in endothelial cells and in perivascular astrocytes [86] . Furthermore, P-gp is highly expressed in many tumors [87] .
MRPs
MRPs in particular are involved in the extrusion of conjugated xenobiotics and the mostly representative transporter of this family, MRP1, is expressed at the luminal site of the brain capillaries. Evidence of the presence of MRP3 and MRP5 proteins at the BBB is reported [88] .
SLC FAMILY IN BBB
The SoLute Carrier (SLC) family comprises 43 subfamilies on the basis of their sequences and recently, three novel families (SLC44-SLC46) have been added. SLC transporters move the solutes employing as a driving force their electrochemical gradient [78] . Some SLC transporters are biochemically classified as coupled transporters, exchangers and as passive transporters.
Each transporter displays distinct pharmacological roles and transports specific substrates, such as amino acids, oligopeptides, sugars, monocarboxylic acids, organic cations, anions, phosphates, nucleosides, metals and water-soluble vitamins.
Among the SLCs, SLC19, SLC28, SLC29, SLC7A, SLC3A and SLC31A modulate chemotherapeutic treatment because these transporters sensitize tumor cells to anticancer drugs.
Polymorphisms of SLC transporters are an important tool to predict the therapeutic response and toxicity of antineoplastic agents and for the survival of patients after chemotherapy.
Some Organic Anion Transporters (OAT1 and OAT3) were monitored on the brush border of the choroids plexus and in an in vitro BBB model [89, 90] . Among organic anions transported by OATs p-aminohippurate, dicarboxylates and -lactam antibiotics are reported [79] .
Also some Organic Cation Transporters (OCT2 in particular) are expressed in the brain [76, 91] . They modulate neurotransmitters in neurons rather than at the BBB. A new family of OCTNs has been also found, that displays significant homology to the OTC and OAT families. Indeed, the first study classified OCTNs as organic cation transporters while recent findings demonstrated their physiological function as sodium ion-dependent transporters for carnitine involved in fatty acids metabolism. Finally, monocarboxylic acid transporters (MTC), detected at both luminal and abluminal membranes of the brain capillaries, are involved in the transport of lactic and pyruvic acids [92] . In particular MCT1 subtype contributes to the regulation of energy substrates in the brain parenchyma at BBB level [93] .
CONCLUSIONS
The active transporters play a crucial role in drug bioavailability and disposition in several compartments such as BBB, BCSFB and GI. The study and the characterization of ABC transporters give perspectives and a new address in drugs discovery. These findings should be addressed by the medicinal chemist in the plan of new drugs optimizing their pharmacodynamic properties by strategies consistent with pharmacokinetic requirements for overcoming biological barriers. Therefore, more predictive biological assays are needed to assess the interaction of drugs with active transporters in order to limit the discrepancies between the encouraging pharmacodynamic in vitro profile and the results found in the in vivo assays because of the involvement of active transporters.
